Cardiac Stem Cell Therapy Company, Cardio³
BioSciences,
Appoints Former New Jersey Medical School Assistant Professor,
Dr. Vinciane Gaussin, as its Chief Scientific Officer (CSO)
“The addition of Dr. Gaussin to our
management team represents an important milestone in our mission to
position Cardio³ BioSciences as a global
leader in the field of regenerative therapies for heart failure.”
- Christian Homsy, MD, CEO, Cardio³
BioSciences
BRAINE L'ALLEUD, Belgium (Business Wire EON/PRWEB ) September 28, 2007 --
Cardio³
BioSciences (www.cardio3bio.com)
announced today the appointment of Vinciane Gaussin, Ph.D., as
its Chief Scientific Officer (CSO), effective immediately.
Most recently, Dr. Gaussin was an Assistant Professor in the Department
of Cell Biology and Molecular Medicine at the University of Medicine
and Dentistry of New Jersey (UMDNJ) since 2000. In 2000, she was the
second-place finalist for the American Heart Association’s
prestigious Louis N. and Arnold M. Katz Basic Science Research Prize
for Young Investigators. From 1997-1999, Dr. Gaussin was a
postdoctoral fellow focusing on developmental biology of the heart at Baylor
College of Medicine. She has authored or co-authored 24 clinical
basic science research papers in such esteemed journals as Biochemistry
Journal, Nature Medicine, Proceedings of the National
Academy of Sciences, Circulation and Developmental Biology.
“The addition of Dr. Gaussin to our management
team represents an important milestone in our mission to position
Cardio³ BioSciences as a global leader in the
field of regenerative therapies for heart failure,”
said Christian Homsy, M.D., CEO of Cardio³
BioSciences. “Over 20 million people worldwide
suffer from chronic heart failure, but in spite of the aggressive
approaches used to treat heart patients, no effective means are
available to repair a damaged heart—yet.
Fortunately, the regenerative potential of stem cells guided toward a
cardiac lineage are expected to change this scenario, and we are looking
forward with great anticipation to our first-in-man procedure scheduled
for the first half of next year.”
In June, the Company announced that it has entered into a collaborative
agreement with Mayo Clinic related to the licensing of Mayo
Clinic research, know-how and intellectual property in the field of cardiac
commitment of stem cells. The research, headed by Prof. André
Terzic and Dr. Atta Behfar at Mayo Clinic, has focused on the
guided commitment of adult as well as embryonic stem cells. The scope of
the license covers heart failure of ischemic and non-ischemic
origin.
Cardio3
BioSciences is a biotechnology company focused on regenerating
heart muscle via cardiac lineage-committed stem cell therapy for
patients with Congestive Heart Failure (CHF). The Company’s
first two products, C-Cure™ and C-Cath™,
are a ‘complete solution’
drug/device combination: C-Cure™ is the first
biotherapeutic designed from autologous stem cells committed to a
cardiac lineage before implantation, developed in collaboration with
Mayo Clinic Molecular Biology Group researchers; C-Cath™
is a proprietary catheter that allows for the accurate transmyocardial
injection of C-Cure™.
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U2luZy1IYWxmLUhvcnItTWFnbi1UaGlyLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.